SRS Capital Advisors Inc. Has $240,000 Stake in Pfizer Inc. (NYSE:PFE)

SRS Capital Advisors Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 15.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,324 shares of the biopharmaceutical company’s stock after selling 1,579 shares during the period. SRS Capital Advisors Inc.’s holdings in Pfizer were worth $240,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of PFE. Los Angeles Capital Management LLC grew its stake in shares of Pfizer by 3.1% in the fourth quarter. Los Angeles Capital Management LLC now owns 29,864 shares of the biopharmaceutical company’s stock worth $860,000 after purchasing an additional 899 shares during the last quarter. First Horizon Advisors Inc. raised its holdings in shares of Pfizer by 1.2% during the fourth quarter. First Horizon Advisors Inc. now owns 498,153 shares of the biopharmaceutical company’s stock valued at $14,342,000 after purchasing an additional 5,692 shares during the period. Coombe Bender & Co LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at about $334,000. First Trust Direct Indexing L.P. increased its position in Pfizer by 17.3% in the 4th quarter. First Trust Direct Indexing L.P. now owns 35,675 shares of the biopharmaceutical company’s stock valued at $1,027,000 after buying an additional 5,269 shares in the last quarter. Finally, DiNuzzo Private Wealth Inc. acquired a new position in Pfizer during the 4th quarter worth approximately $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of several recent research reports. Morgan Stanley boosted their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. BMO Capital Markets reissued an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $36.00.

Pfizer Trading Up 0.4 %

Shares of PFE traded up $0.11 during trading hours on Friday, hitting $27.81. The company had a trading volume of 60,568,852 shares, compared to its average volume of 41,900,304. The firm has a market cap of $157.48 billion, a P/E ratio of -463.42, a P/E/G ratio of 1.18 and a beta of 0.63. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37. The stock’s 50 day moving average price is $26.88 and its 200 day moving average price is $28.25. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The business’s quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.23 EPS. On average, research analysts predict that Pfizer Inc. will post 2.36 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.04%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.